cCAM Biotherapeutics
Monoclonal Antibodies for Cancer Treatment
Company Overview
Snapshot
Founded in January 2010, cCAM Biotherapeutics operated with 1–10 employees. The company raised a total of $8 million across one funding round and was acquired by Merck in July 2015.
Business overview
cCAM Biotherapeutics was a preclinical-stage company focused on the discovery and development of novel immunotherapies for cancer treatment. Its core product, CM-24, was a phase 1 monoclonal antibody designed to inhibit the immunosuppressive effect of CEACAM1, thereby enhancing the anti-tumor immune response of T and NK cells. The company operated within the Pharmaceuticals sector, specifically targeting the Drugs Discovery & Development and Pharma & Medical Biotechnology industries with its biologicals-based solutions.
Strategic signal
In April 2015, cCAM Biotherapeutics announced the initiation of a Phase 1 trial for CM-24, a novel immune checkpoint inhibitor for cancer immunotherapy. This milestone signaled significant progress in advancing its lead product toward clinical validation, demonstrating the company's capability to translate preclinical research into human trials and attracting the attention of major pharmaceutical players like Merck, which subsequently acquired the company.
Company Intelligence Q&A
- What is cCAM Biotherapeutics' primary focus?
- cCAM Biotherapeutics focused on the discovery and development of novel immunotherapies for cancer treatment, utilizing monoclonal antibodies.
- When was cCAM Biotherapeutics founded?
- cCAM Biotherapeutics was founded in January 2010.
- What was the key product developed by cCAM Biotherapeutics?
- The key product developed by cCAM Biotherapeutics was CM-24, a phase 1 monoclonal antibody designed to inhibit the immunosuppressive effect of CEACAM1 for enhanced anti-tumor immune response.
- When did cCAM Biotherapeutics initiate its Phase 1 trial for CM-24?
- cCAM Biotherapeutics announced the initiation of its Phase 1 trial for CM-24 in April 2015.
- Who acquired cCAM Biotherapeutics?
- cCAM Biotherapeutics was acquired by Merck in July 2015.